Huang Haige, Tian Jun, Xu Xin, Liang Qiong, Huang Xusen, Lu Jiaming, Yao Yongliang
Department of Gastrointestinal Surgery, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, P.R. China.
J BUON. 2018 May-Jun;23(3):659-664.
To observe the infection rates of Helicobacter pylori (HP) in bile reflux gastritis (BRG) and gastric cancer and the clinical significance of HP eradication in BRG and gastric cancer patients complicated with HP.
248 patients diagnosed with BRG and gastric cancer via gastroscopy were enrolled in this study. HP detection and infection rates of HP were evaluated. Then, BRG and gastric cancer patients complicated with HP were randomly divided into BRG group 1, BRG group 2, gastric cancer group 1 and gastric cancer group 2. BRG group 1 and gastric cancer group 1 were treated with conventional anti-inflammatory drugs for 10 days, and BRG group 2 and gastric cancer group 2 were treated with anti-HP drugs in addition to conventional anti-inflammatory drugs. One month after drug withdrawal, the infection rates of HP in each group were evaluated, and prognostic follow-up was performed to record the post-therapy patient conditions.
HP infection rate was 35.8% (57/159) in the BRG group and 73.0% (65/89) in the gastric cancer group, with statistically significant difference (p<0.01). In patients treated with anti-HP drugs had the HP infection rate effectively reduced. The treatment effective rates of patients with BRG and gastric cancer complicated with HP infection after eradication of HP were 82.8 and 68.8%, respectively, while those of patients with non-eradicated HP were only 46.4 and 37.5 %, respectively. The differences between the two groups were statistically significant (p<0.05).
HP is directly and closely related to the occurrence of gastric diseases, HP infection rate in patients with gastric cancer is significantly higher than that in patients with BRG, and the treatment of HP can effectively improve the rehabilitation rate in patients with gastric diseases.
观察胆汁反流性胃炎（BRG）和胃癌中幽门螺杆菌（HP）的感染率，以及根除HP对BRG和合并HP的胃癌患者的临床意义。
纳入248例经胃镜诊断为BRG和胃癌的患者。评估HP检测及HP感染率。然后，将合并HP的BRG和胃癌患者随机分为BRG组1、BRG组2、胃癌组1和胃癌组2。BRG组1和胃癌组1用常规抗炎药治疗10天，BRG组2和胃癌组2除常规抗炎药外还加用抗HP药物。停药1个月后，评估各组HP感染率，并进行预后随访以记录治疗后患者情况。
BRG组HP感染率为35.8%（57/159），胃癌组为73.0%（65/89），差异有统计学意义（p<0.01）。使用抗HP药物治疗的患者HP感染率有效降低。根除HP后，合并HP感染的BRG和胃癌患者的治疗有效率分别为82.8%和68.8%，而未根除HP的患者分别仅为46.4%和37.5%。两组间差异有统计学意义（p<0.05）。
HP与胃部疾病的发生直接密切相关，胃癌患者的HP感染率显著高于BRG患者，治疗HP可有效提高胃部疾病患者的康复率。
